Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS

Yoshihisa Shitara, Masaru Hirano, Yasuhisa Adachi, Tomoo Itoh, Hitoshi Sato and Yuichi Sugiyama
Drug Metabolism and Disposition December 2004, 32 (12) 1468-1475; DOI: https://doi.org/10.1124/dmd.32.12.1468
Yoshihisa Shitara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Hirano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhisa Adachi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoo Itoh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitoshi Sato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuichi Sugiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Previously, we have shown that the inhibition of the transporter-mediated hepatic uptake of cerivastatin (CER) by cyclosporin A (CsA) could, at least partly, explain a pharmacokinetic interaction between these drugs in humans. In the present study, we have examined the effect of CsA on the in vivo disposition of CER in rats and the in vitro uptake of [14C]CER in isolated rat hepatocytes in an attempt to evaluate the effect of inhibition of transporter-mediated hepatic uptake on the in vivo CER disposition. The steady-state plasma concentration of CER increased 1.4-fold when coadministered with CsA up to a steady-state blood concentration of 4 μM. Studies of [14C]CER uptake into isolated rat hepatocytes showed saturable transport, with the saturable portion accounting for more than 80% of the total uptake. CsA competitively inhibited the uptake of [14C]CER with a Ki of 0.3 μM. The IC50 for the uptake of [14C]CER in the absence and presence of rat plasma was 0.2 and 2.3 μM, respectively. The in vivo hepatic uptake of [14C]CER evaluated by the liver uptake index method was also inhibited by CsA in a dose-dependent manner. On the other hand, CsA did not inhibit the metabolism of [14C]CER in rat microsomes. The in vitro and in vivo correlation analysis revealed that this pharmacokinetic interaction between these drugs in rats could be quantitatively explained by the inhibition of transporter-mediated hepatic uptake. Thus, this drug-drug interaction in rats is predominantly caused by the transporter-mediated uptake process.

Footnotes

  • This study was, in part, supported by the Grant-in-Aid for Young Scientists (B) provided by the Ministry of Education, Culture, Sports, Science and Technology of Japan (Y.Sh.), Grant-in-Aid for the Advanced and Innovational Research program in Life Sciences (Y.Su.) and for the 21st Century Center of Excellence program provided by the Ministry of Education, Culture, Sports, Science and Technology, Japan (Y.Su.).

  • ABBREVIATIONS: CER, cerivastatin; AUC, area under the plasma concentration-time curve; CLH, hepatic clearance; CLint, intrinsic hepatic clearance; CLint,all, overall intrinsic hepatic clearance; CLtot, total body clearance; CLuptake, uptake clearance; CsA, cyclosporin A; CYP2C8, cytochrome P450 2C8; DDI, drug-drug interaction; fb, blood unbound fraction; HEK, human embryonic kidney; HPLC, high performance liquid chromatography; IC50, inhibitor concentration to produce a 50% reduction in the transport; KHB, Krebs-Henseleit buffer; Ki, inhibition constant; Km, Michaelis constant; LUI, liver uptake index; OATP/Oatp, organic anion transporting polypeptide; Pdif, nonsaturable uptake clearance; PSu,efflux, membrane permeability clearance of the unbound drug for the efflux process; PSu,influx, membrane permeability clearance of the unbound drug for the influx process; SD rat, Sprague-Dawley rat; Vmax, maximum uptake rate.

    • Received March 18, 2004.
    • Accepted September 14, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 32 (12)
Drug Metabolism and Disposition
Vol. 32, Issue 12
1 Dec 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS

Yoshihisa Shitara, Masaru Hirano, Yasuhisa Adachi, Tomoo Itoh, Hitoshi Sato and Yuichi Sugiyama
Drug Metabolism and Disposition December 1, 2004, 32 (12) 1468-1475; DOI: https://doi.org/10.1124/dmd.32.12.1468

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS

Yoshihisa Shitara, Masaru Hirano, Yasuhisa Adachi, Tomoo Itoh, Hitoshi Sato and Yuichi Sugiyama
Drug Metabolism and Disposition December 1, 2004, 32 (12) 1468-1475; DOI: https://doi.org/10.1124/dmd.32.12.1468
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics